Stereotaxis, CardioFocus collab on robotic PFA for cardiac arrhythmias

Stereotaxis (NYSE:STXS) announced today that it partnered with CardioFocus to advance robotic pulsed field ablation (PFA) technology.

The companies hope to combine both of their proprietary technologies to accelerate the robotic PFA technology toward commercialization. They hope to bring to market the first-ever robotic PFA solution for treating cardiac arrhythmias, according to a news release.

CardioFocus develops the Centauri PFA system, a CE-marked platform used to treat more than 9,000 patients to date across Europe. open-platform PFA system, supports focal contact force catheter workflows. It leverages a custom monopolar waveform designed to achieve transmural lesions while eliminating microbubbles and muscle stimulation. The system enables durable PFA lesions while enhancing procedural efficiency, safety and patient outcomes.

See full article (https://www.massdevice.com/stereotaxis-cardiofocus-collab-robotic-pfa-arrhythmias/)